Journal article icon

Journal article

Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

Abstract:

Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examin...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1177/1352458520943791

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Clinical Neurosciences
Role:
Author
Expand authors...
Publisher:
SAGE Publications Publisher's website
Journal:
Multiple Sclerosis Journal Journal website
Volume:
26
Issue:
10
Pages:
1261-1264
Place of publication:
England
Publication date:
2020-08-07
Acceptance date:
2020-06-22
DOI:
EISSN:
1477-0970
ISSN:
1352-4585
Pmid:
32762494

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP